	US 12,263,153 B2
	Pharmaceutical composition, methods for treating and uses thereof
Maximilian von Eynatten, Wiesbaden (DE); Uli Christian Broedl, Oakville (CA); and Hans-Juergen Woerle, Grandvaux VD (CH)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Jun. 3, 2022, as Appl. No. 17/831,460.
Application 17/831,460 is a continuation of application No. 17/094,045, filed on Nov. 10, 2020, abandoned.
Application 17/094,045 is a continuation of application No. 16/738,116, filed on Jan. 9, 2020, abandoned.
Application 16/738,116 is a continuation of application No. 15/806,389, filed on Nov. 8, 2017, abandoned.
Claims priority of provisional application 62/514,249, filed on Jun. 2, 2017.
Claims priority of provisional application 62/420,062, filed on Nov. 10, 2016.
Prior Publication US 2022/0288012 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7048 (2006.01); A61K 9/20 (2006.01); A61K 31/351 (2006.01); A61K 45/06 (2006.01); A61P 13/12 (2006.01)

CPC A61K 31/351 (2013.01) [A61K 9/2018 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61P 13/12 (2018.01)]

30 Claims

1. A method for reducing the risk of cardiovascular death in a patient with chronic kidney disease, the method comprising administering a pharmaceutically effective amount of empagliflozin to the patient.